{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28CTLA-4%29&page=8", "query": { "intervention": "MDX-010 (CTLA-4)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 238, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28CTLA-4%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28CTLA-4%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T08:47:40.538Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04248569", "title": "DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fibrolamellar Hepatocellular Carcinoma (FLC)" ], "interventions": [ { "name": "DNAJB1-PRKACA peptide vaccine", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 56, "start_date": "2020-04-20", "completion_date": "2034-03-01", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04248569" }, { "nct_id": "NCT01804465", "title": "Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "SipT Treatment", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2014-04-22", "completion_date": "2020-08-31", "has_results": true, "last_update_posted_date": "2021-08-18", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 2, "location_summary": "San Francisco, California • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804465" }, { "nct_id": "NCT04013542", "title": "Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Gene Rearrangement", "EGFR Gene Mutation", "Locally Advanced Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-09-13", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04013542" }, { "nct_id": "NCT02254772", "title": "A Phase I/II Study of Intratumoral Injection of SD-101", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "SD-101", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Robert Lowsky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-09", "completion_date": "2017-01-26", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02254772" }, { "nct_id": "NCT04149275", "title": "Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinosarcoma of Ovary", "Carcinosarcoma of Uterus", "Carcinosarcoma of Vagina" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2021-02", "completion_date": "2021-02", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04149275" }, { "nct_id": "NCT03449108", "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Sarcoma", "Dedifferentiated Chondrosarcoma", "Giant Cell Tumor of Bone", "Malignancy in Giant Cell Tumor of Bone", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Platinum-Resistant Ovarian Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Osteosarcoma", "Recurrent Ovarian Carcinoma", "Refractory Osteosarcoma", "Soft Tissue Sarcoma", "Thyroid Gland Anaplastic Carcinoma", "Thyroid Gland Squamous Cell Carcinoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2018-04-27", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449108" }, { "nct_id": "NCT04326257", "title": "Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Nivolumab+Relatlimab", "type": "DRUG" }, { "name": "Nivolumab+Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-05-14", "completion_date": "2024-08-12", "has_results": true, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04326257" }, { "nct_id": "NCT01693783", "title": "Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Squamous Cell Carcinoma", "Human Papillomavirus Infection", "Recurrent Cervical Carcinoma", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVB Cervical Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2012-12-03", "completion_date": "2021-11-24", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 5, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01693783" }, { "nct_id": "NCT03914300", "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Follicular Variant Thyroid Gland Papillary Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Follicular Carcinoma", "Thyroid Gland Oncocytic Carcinoma", "Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-02-10", "completion_date": "2026-12-17", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 33, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914300" }, { "nct_id": "NCT03459222", "title": "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "BMS-986205", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2018-05-30", "completion_date": "2025-02-19", "has_results": true, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-15T08:47:40.538Z", "location_count": 5, "location_summary": "Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03459222" } ] }